Alnylam Pharma (ALNY) Tops Q2 EPS by 91c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $288.18 +0.62%
Revenue Growth %: +70.6%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +70.6%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $0.32, $0.91 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $773.69 million versus the consensus estimate of $643.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Morgan Stanley Upgrades Global Unichip Corp (3443:TT) to Overweight
- St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
